AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7862837 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg)
Number of subjects: 0
Study 7862837 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (2 mg)
Number of subjects: 0
Study 7862837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 7862837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 0
Study 7862837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2644129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (3 g/m2 every 12 hours during 3 h of infusion)
Number of subjects: 125
Study 2644129 — intervention group
Group type: COMPARATOR
Intervention: Addition of standard maintenance treatment after consolidation with 4 courses of DAT (Daunorubicin + Ara-C + 6-Thioguanine)
Number of subjects: 125
Study 2644129 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ara-C
Number of subjects: 125
Study 301745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (acute single dose)
Number of subjects: 20
Study 301745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (chronic multiple dose)
Number of subjects: 20
Study 301745 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (high dosage open study)
Number of subjects: 20
Study 301745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acute single dose)
Number of subjects: 20
Study 301745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic multiple dose)
Number of subjects: 20
Study 301745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high dosage open study)
Number of subjects: 20
Study 30878156 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Addiction (FA)
Number of subjects: 644
Study 30878156 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor Sleep Quality
Number of subjects: 644
Study 30878156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotype Distribution
Number of subjects: 644
Study 30878156 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations with YFAS score
Number of subjects: 644
Study 30681352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractured limbs of case horses
Number of subjects: 114
Study 30681352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfractured limbs of case horses
Number of subjects: 114
Study 30681352 — intervention group
Group type: COMPARATOR
Intervention: Limbs of control horses
Number of subjects: 114
Study 29048511 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI, including local protocol implementation, education sessions, and feedback.
Number of subjects: 242534
Study 29048511 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the 2011 national guidelines on antibiotic prescriptions for ARTI.
Number of subjects: 242534
Study 25728688 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention for PTSS, depression, and anxiety (10-week program based on cognitive behavior therapy)
Number of subjects: 58
Study 25728688 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help intervention for depression and anxiety
Number of subjects: 58
Study 25728688 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 58
Study 23742144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric score based on clinical status, echo Doppler variables, NT-proBNP, eGFR, and drug therapies.
Number of subjects: 638
Study 21767341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial insulin aspart three times daily
Number of subjects: 708
Study 21767341 — intervention group
Group type: COMPARATOR
Intervention: Biphasic insulin aspart twice‐daily
Number of subjects: 708
Study 21767341 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin detemir once‐daily (twice if required)
Number of subjects: 708
Study 21767341 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI gain > 1.23 kg/m²
Number of subjects: 708
Study 21767341 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of hypoglycaemia
Number of subjects: 708
Study 19957839 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 215
Study 19957839 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy (OD)
Number of subjects: 215
Study 16978619 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole + rFSH
Number of subjects: 41
Study 16978619 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate + rFSH
Number of subjects: 41
Study 15133775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch, nicotine gum, or bupropion (33-50% of patients)
Number of subjects: 111
Study 15133775 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quitting self-efficacy, risk perceptions, and perceived benefits of quitting
Number of subjects: 111
Study 15133775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower tobacco use and nicotine addiction, shorter time since diagnosis
Number of subjects: 111
Study 15133775 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms, low quitting self-efficacy, low perceived risk, low perceived benefits of quitting
Number of subjects: 111
Study 11126337 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt containing a novel fat emulsion (5g of a novel fat emulsion + 1g milk fat)
Number of subjects: 59
Study 11126337 — intervention group
Group type: COMPARATOR
Intervention: Control yoghurt (6g milk fat)
Number of subjects: 59
Study 11126337 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt containing a novel fat emulsion
Number of subjects: 59
Study 9145142 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective delay TRAM flap
Number of subjects: 28
Study 9145142 — intervention group
Group type: COMPARATOR
Intervention: Standard TRAM flap
Number of subjects: 28
Study 9145142 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed TRAM flap
Number of subjects: 28
Study 8437976 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline short-term infusion (420 mg theophylline)
Number of subjects: 16
Study 8437976 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline short-term infusion (theophylline component 351.3 mg)
Number of subjects: 16
Study 8437976 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and aminophylline infusions
Number of subjects: 16
Study 3511103 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% Sanguinarine mouthwash
Number of subjects: 21
Study 3511103 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Chlorhexidine mouthwash
Number of subjects: 21
Study 3511103 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 21
Study 30854916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha extract (Shoden beads, 21 mg of withanolide glycosides per day)
Number of subjects: 57
Study 30854916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 30110693 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily with tramadol hydrochloride 50 mg twice daily (as required)
Number of subjects: 72
Study 30110693 — intervention group
Group type: COMPARATOR
Intervention: Tramadol hydrochloride 50 mg twice daily for 6 weeks
Number of subjects: 72
Study 30110693 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 72
Study 26345262 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (post-ICD implantation)
Number of subjects: 42
Study 24901856 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, amoxicillin, and metronidazole)
Number of subjects: 55
Study 24901856 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, tetracycline, metronidazole, and bismuth subcitrate)
Number of subjects: 55
Study 24901856 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (both therapies combined)
Number of subjects: 55
Study 22618567 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine-lamivudine-nevirapine (d4T/3TC/NVP)
Number of subjects: 63
Study 22618567 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine-lamivudine-efavirenz (d4T/3TC/EFV)
Number of subjects: 63
Study 22618567 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP
Number of subjects: 63
Study 22618567 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV
Number of subjects: 63
Study 22618567 — intervention group
Group type: EXPERIMENTAL
Intervention: N348I in the context of polymerase domain mutations
Number of subjects: 63
Study 20183706 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0
Study 20183706 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 0
Study 20183706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial skills in women
Number of subjects: 0
Study 20183706 — intervention group
Group type: COMPARATOR
Intervention: Spatial skills in men
Number of subjects: 0
Study 17984816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib‐MenC‐TT vaccine
Number of subjects: 100
Study 15691312 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line triple therapy (7 days of omeprazole, amoxicillin and clarithromycin twice a day)
Number of subjects: 49
Study 15691312 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line quadruple therapy (7 days of omeprazole twice a day, plus tetracycline, metronidazole and bismuth subcitrate three times a day)
Number of subjects: 49
Study 15691312 — intervention group
Group type: COMPARATOR
Intervention: Triple first strategy
Number of subjects: 49
Study 15691312 — intervention group
Group type: COMPARATOR
Intervention: Quadruple first strategy
Number of subjects: 49
Study 11836733 — intervention group
Group type: EXPERIMENTAL
Intervention: Common methods of analysis for count data in the presence of selection criteria
Number of subjects: 0
Study 11836733 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from an epilepsy trial
Number of subjects: 0
Study 11836733 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from a study of transient myocardial ischaemia
Number of subjects: 0
Study 9706929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (10 microg/kg i.m. 15 min before anesthesia)
Number of subjects: 1066
Study 9706929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids (lactated Ringer's solution 15 mL/kg within 15 min before spinal anesthesia)
Number of subjects: 1066
Study 9706929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 1066
Study 9706929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of both sedatives and opioids (subgroup)
Number of subjects: 1066
Study 7620695 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol hydrochloride
Number of subjects: 24
Study 2490833 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 10940
Study 2490833 — intervention group
Group type: COMPARATOR
Intervention: Referred care
Number of subjects: 10940
Study 336818 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (S-CMC; Mucodyne, Berk Pharmaceuticals)
Number of subjects: 52
Study 336818 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 52
Study 31652226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional cryosurgery
Number of subjects: 31
Study 31652226 — intervention group
Group type: COMPARATOR
Intervention: Electrosurgery
Number of subjects: 31
Study 30888743 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile anesthetics (desflurane, isoflurane, or sevoflurane)
Number of subjects: 5400
Study 30888743 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 5400
Study 28569455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 34
Study 28569455 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training (ST)
Number of subjects: 34
Study 28569455 — intervention group
Group type: COMPARATOR
Intervention: Control group (Con)
Number of subjects: 34
Study 25900169 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal glove and gown use during all patient contact in ICUs
Number of subjects: 1800
Study 23838159 — intervention group
Group type: EXPERIMENTAL
Intervention: r-FSH and r-LH (Luveris 150 IU/day)
Number of subjects: 253
Study 23838159 — intervention group
Group type: COMPARATOR
Intervention: r-FSH only
Number of subjects: 253
Study 21217461 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive locomotor training with an electromechanical gait trainer (Gait Trainer GT I) plus 10 mins of passive joint mobilization and stretching exercises
Number of subjects: 18
Study 21217461 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 18
Study 19190781 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (mass distribution)
Number of subjects: 16
Study 19190781 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment observation
Number of subjects: 16
Study 16417762 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical banded gastroplasty (VBG)
Number of subjects: 100
Study 16417762 — intervention group
Group type: COMPARATOR
Intervention: Lap-Band surgery
Number of subjects: 100
Study 16417762 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study 15486960 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (Seroquel)
Number of subjects: 1106
Study 11318837 — intervention group
Group type: COMPARATOR
Intervention: No retinopathy
Number of subjects: 3709
Study 11318837 — intervention group
Group type: COMPARATOR
Intervention: Microaneurysms (MA) in one eye only
Number of subjects: 3709
Study 11318837 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe retinopathy features
Number of subjects: 3709
Study 11318837 — intervention group
Group type: COMPARATOR
Intervention: No retinopathy at 6 years
Number of subjects: 3709
Study 11318837 — intervention group
Group type: EXPERIMENTAL
Intervention: More severe retinopathy
Number of subjects: 3709
Study 9643620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bambuterol
Number of subjects: 8
Study 9643620 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline
Number of subjects: 8
Study 9643620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bambuterol (single dose and repeated doses once daily for 7 days)
Number of subjects: 8
Study 9643620 — intervention group
Group type: EXPERIMENTAL
Intervention: Generated terbutaline from oral bambuterol
Number of subjects: 8
Study 9643620 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral dosing of bambuterol
Number of subjects: 8
Study 7945745 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP, 0.5 mg/kg p.o.)
Number of subjects: 43
Study 7945745 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 43
Study 7945745 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TRP, 100 mg/kg i.v.)
Number of subjects: 43
Study 7945745 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (L-TRP)
Number of subjects: 43
Study 3074860 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention Enactive
Number of subjects: 0
Study 3074860 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention Symbolic
Number of subjects: 0
Study 3074860 — intervention group
Group type: COMPARATOR
Intervention: Education Only
Number of subjects: 0
Study 3074860 — intervention group
Group type: COMPARATOR
Intervention: Routine Treatment
Number of subjects: 0
Study 3074860 — intervention group
Group type: COMPARATOR
Intervention: Low-EE groups (Education Only and Routine Treatment)
Number of subjects: 0
Study 3074860 — intervention group
Group type: COMPARATOR
Intervention: High-EE relatives (no active intervention)
Number of subjects: 0
Study 3074860 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Intervention groups
Number of subjects: 0
Study 3074860 — intervention group
Group type: COMPARATOR
Intervention: Education Only and Routine Treatment groups
Number of subjects: 0
Study 3074860 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study 29083501 — intervention group
Group type: EXPERIMENTAL
Intervention: DESMOND-ID programme (n = 19)
Number of subjects: 39
Study 29083501 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 39
Study 27010635 — intervention group
Group type: COMPARATOR
Intervention: Coffee consumption >3 to 7 cups/day
Number of subjects: 91767
Study 27010635 — intervention group
Group type: COMPARATOR
Intervention: Coffee consumption >7 cups/day
Number of subjects: 91767
Study 27010635 — intervention group
Group type: COMPARATOR
Intervention: Coffee consumption >5 cups/day in never smokers
Number of subjects: 91767
Study 27010635 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 91767
Study 26242644 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care (n=391)
Number of subjects: 781
Study 26242644 — intervention group
Group type: COMPARATOR
Intervention: Secondary care (n=390)
Number of subjects: 781
Study 23763412 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-focused sexual risk reduction intervention
Number of subjects: 0
Study 23763412 — intervention group
Group type: COMPARATOR
Intervention: General health promotion intervention
Number of subjects: 0
Study 20581214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral celecoxib from the evening before surgery until 48 hours after operation.
Number of subjects: 40
Study 20581214 — intervention group
Group type: COMPARATOR
Intervention: Placebo from the evening before surgery until 48 hours after operation.
Number of subjects: 40
Study 18346185 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1913
Study 16901414 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0
Study 14649342 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve blockade
Number of subjects: 60
Study 14649342 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: PPR (physiological pattern release) verapamil hydrochloride
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-atenolol combination
Number of subjects: 1032
Study 10826461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: PPR verapamil
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (gastrointestinal system)
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom distress
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom distress change (1 step)
Number of subjects: 1032
Study 10826461 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme change in symptom distress
Number of subjects: 1032
Study 8701624 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefotiam
Number of subjects: 97
Study 8701624 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg clindamycin
Number of subjects: 97
Study 25025189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy treatment (three individual sessions each week for four weeks)
Number of subjects: 20
Study 6347743 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 96
Study 6347743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31082897 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ligation of inferior mesenteric artery (LL)
Number of subjects: 214
Study 31082897 — intervention group
Group type: COMPARATOR
Intervention: High ligation of inferior mesenteric artery (HL)
Number of subjects: 214
Study 27727066 — intervention group
Group type: COMPARATOR
Intervention: CIS (radiation-cisplatin without cetuximab)
Number of subjects: 818
Study 27727066 — intervention group
Group type: EXPERIMENTAL
Intervention: CET/CIS (radiation-cisplatin with cetuximab)
Number of subjects: 818
Study 27727066 — intervention group
Group type: EXPERIMENTAL
Intervention: p16-positive OPC patients
Number of subjects: 818
Study 27727066 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment PSS-HN diet, PSS-HN eating, FACT-HN, and EQ-5D index scores
Number of subjects: 818
Study 27727066 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline FACT-HN total, functional, physical subscale, and EQ-5D index scores
Number of subjects: 818
Study 27220601 — intervention group
Group type: EXPERIMENTAL
Intervention: Rutin-containing cream
Number of subjects: 40
Study 27220601 — intervention group
Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 40
Study 24731895 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training (practiced three times per week for six months)
Number of subjects: 172
Study 24731895 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual routine care)
Number of subjects: 172
Study 24731895 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong training
Number of subjects: 172
Study 22658702 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (1 mg/kg per day) for 90 days
Number of subjects: 35
Study 22658702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 22658702 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 35
Study 20870668 — intervention group
Group type: COMPARATOR
Intervention: CPAP 2 cm H2O (CPAP2; n=25)
Number of subjects: 75
Study 20870668 — intervention group
Group type: COMPARATOR
Intervention: CPAP 5 cm H2O (CPAP5; n=25)
Number of subjects: 75
Study 20870668 — intervention group
Group type: EXPERIMENTAL
Intervention: HFPPV (n=25)
Number of subjects: 75
Study 17434245 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Step Length
Number of subjects: 21
Study 15377651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (10 mg)
Number of subjects: 21
Study 15377651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous adenosine (10 mg) during hyperoxia
Number of subjects: 21
Study 15377651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21